Drs. Lefkowitz and Kobilka took a molecular and structural approach to reveal the most basic biochemical and mechanistic detail of GPCR function. [6] [7] [8] Their work provides a chemical insight into the way GPCRs receive and deliver cellular signals across the plasma membrane. Most importantly, due to their discoveries, the therapeutic potential of GPCRs can now be more efficiently mined. They indeed fully deserve the Chemistry Prize, albeit with a medical flavor.
The pathway that leads GPCRs to the Nobel Prize
How a cell mediates the exchange of extracellular information into intracellular chemical messages has puzzled generations of scientists. Although the concept of ligand-activated receptor was noted more than a century ago, the molecular identification and characterization of receptor molecules has been slow to say the least. [9] In 1970s, Prof. Lefkowitz was one of the first to demonstrate successfully the existence of specific cell surface receptors for endocrine hormones. [10] [11] [12] By using chemically synthesized radioactive ligands, he showed the specific binding of adrenocortiotropic hormone (ACTH) and epinephrine to distinct receptors that are able to activate adenylyl cyclase. [10] [11] [12] He later focused on the studies of bARs and proposed the ternary complex model to explain how cells convert extracellular stimuli into intracellular signals. [13] This model dictated that the ligand-receptor interaction leads to the formation of a high-affinity receptor complex where a cell surface receptor is coupled at both ends to the extracellular agonist (ligand) and intracellular G-protein, respectively. [13] The isolation and purification of functional bAR was achieved some years later after efficient detergent solubilization, followed by ligand-specific affinity chromatography. [14, 15] The functional identity of the isolated receptor was proven after reconstitution of the purified receptor with G proteins and adenylyl cyclase. [16, 17] Subsequent N-terminal amino acid sequencing revealed unique peptide sequences from which degenerate oligonucleotide probes were derived, allowing Prof. Kobilka to successfully clone the bAR gene. [18, 19] The delineation of the full-length bAR protein sequence uncovered a major structural surprise: The presence of the seven transmembrane (7TM) helices that shared some sequence similarity with the visual pigment protein rhodopsin. [9, 20] Rhodopsin, a 7TM cell surface protein, was already a well-known G-protein-linked receptor at the time. [21, 22] Thus, a structural signature was appreciated among light-sensitive proteins and hormone and neurotransmitter receptors. This realization and molecular cloning of other G-protein-linked receptor genes finally cemented the common 7TM structural feature for the GPCR family. [3, 9, 20] With the development of molecular cloning techniques in the 1980s, site-directed mutagenesis and chimeric receptors were employed to reveal the structural-functional relationship of GPCRs. [9, 20, 23] These studies identified specific receptor sub-domains important for ligand binding and G-protein coupling. [24, 25] In addition, constitutively active receptors were discovered when specific residues were mutated, providing a relevant insight into specific human diseases. [26] During the same period, another convergent theme was also noted among many GPCRs, namely ligand-induced receptor phosphorylation and inactivation or desensitization. [9, 20, 23] The identification of GPCR kinases (GRKs) and b-arrestins not only provided molecular explanation for GPCR desensitization but also led to the demonstration of G-protein-independent signaling mechanisms as well as GPCR endocytosis and recycling. It is accepted now that G proteins, in fact, represent only part of the signaling adaptors used by GPCRs. [27, 28] Structural-functional analysis also noted distinct structural alterations in different states of receptor activation. To achieve this, a multitude of biochemical and biophysical methods were developed and employed to dissect the structural transitions of receptors. [9, 20, 23] It was appreciated from these studies that the structural alterations are key to the understanding of receptor activation mechanism. [29, 30] Thus, a high-resolution structure of GPCRs was necessary for the detailed analysis of the conformational changes in activated and non-activated states, even though it is notoriously difficult to crystallize the membrane proteins. Dr. Palczewski and colleagues were the first to solve the 3D structure of bovine rhodopsin, a highly enriched GPCR in bovine rod outer segment membranes, providing initial insights into the localization of the TM helices in the mem- [31] Soon after, a major breakthrough was achieved when Kobilka's laboratory reported the crystal structure of inverse agonist-bound bAR that was stabilized by an antibody in a lipid environment. [32] This was quickly followed by a more defined structure from the same group after an engineered bAR-T4 lysozyme fusion protein generated a better crystal. [33, 34] Finally, the structure of an active ternary receptor complex containing agonist-bound bAR coupled to G proteins was solved in 2011 by Kobilka and colleagues. [35] When compared with the structure of non-activated bAR, the conformational changes in the activated receptor revealed a sequential event leading to the activation of G protein. In short, ligand binding induced a major displacement of the 6 th TM segment of receptor, exposing a hydrophobic cleft into which the C-terminal helix of Ga protein was able to insert. This interaction in turn changed the G protein structure, eventually leading to its activation. [6] [7] [8] The biochemical methodologies developed for the bAR structural study are now being adapted and applied to solve the structure of other GPCRs. With the detailed 3D structure of the active ternary bAR complex and others, it is possible to screen for better small molecule agonist/ antagonist/inverse agonist more efficiently. This should revolutionize the development of pharmacologic research for drugs targeting GPCRs.
GPCRs and their (bio) chemical significance
The aforementioned summary of the groundbreaking work done by the two Nobel Laureates has emphasized the general biological importance of GPCRs. The following sections will focus on the specific aspects that highlight the (bio) chemical significance of GPCRs in health and disease.
Ligands
GPCRs are known to interact with a plethora of ligands ranging from photons, ions, amino acids, odorants, pheromones, eicosanoids, neurotransmitters, peptides, proteins, and hormones. [3, 36] Thus, a wealth of chemical signals can be deciphered by distinct GPCRs. This versatile ability is in part determined by the diversity in receptor protein sequences that share different degrees of similarity or phylogenetic relationship. Recently, the GRAFS classification system grouped all human GPCRs into Glutamate, Rhodopsin, Adhesion, Frizzled/Taste, and Secretin families based on the phylogenetic criteria. [1] Interestingly, natural ligands to the individual GPCR families also seem to vary considerably. For example, most Glutamate-class GPCRs bind to amino acids, cations, or small organic compounds, the Secretin-class receptors interact mostly with peptide or protein hormone, while the Rhodopsin-class receptors can couple with substances such as photons, nucleotides, lipid-like compounds, peptides, and proteins (including enzymes). The Adhesion-class GPCRs are known to interact with cell surface or extracellular matrix proteins, glycosaminoglycans, or even microbial ligands. [1] Nevertheless, for the majority of GPCRs, the identity of their natural ligands is still unknown, hence remain orphan receptors.
In general, based on their effect on the receptor function, ligands can be classified as agonists, antagonists, or inverse agonists. [5, 36] Agonists exert a positive signaling response, while inverse agonists decrease constitutive signaling activity. Antagonists compete and inhibit the binding of agonists but do not produce any response by themselves. Studies have shown that while many GPCR ligands are found to be full agonists, quite a few, in fact, function as partial agonists suggesting that ligand-induced GPCR activation is more complex than predicted previously. The reason for such differential activations might be explained by the fact that GPCRs may adopt multiple conformational states with different signaling abilities. [23] Molecular studies have shown that while ligand binding activates GPCRs by commonly inducing a conformational change in the 7TM core domain, they do so through rather diverse mechanisms. [37] Most small ligands bind in a cavity formed within the TM region, but peptide and protein ligands might also interact with the N-terminal region and the extracellular loops. In the case of rhodopsin, photon, in fact, activates retinol molecule that is covalently linked in the TM cavity, changing its conformation from cis to trans configuration to activate the receptor. [38] [39] [40] [41] In protease-activated receptors (PARs), activation is brought about by the proteolytic cleavage of the N-terminus of receptors by serine proteases (such as thrombin and trypsin). Part of the newly cleaved receptors then act as an agonist that in turn binds and activates the receptors. [42, 43] Thus, it seems that GPCRs have evolved successfully to adapt various mechanisms to respond to a diverse array of ligands for activation. Indeed, GPCRs represent a treasure trove for ligand identification and potential drug targets. [4, 44, 45] 
Conformational (structural) variants of GPCRs
The conventional view of GPCR activation is that the receptor exists in two conformational states: Inactive and active. Agonist binding stabilized the active form of the receptor, while inverse agonist secured the inactive form. Intracellular signaling is achieved by the active conformation that allowed the efficient coupling and activation of G proteins and downstream adaptor molecules.
However, recent studies have suggested that the mechanisms of receptor activation are far more complex than the simple biomodal switch system. [46] [47] [48] First of all, multiple (more than two) conformational variants of GP-CRs are likely to be present in equilibrium in the plasma membrane. Each GPCR conformation can potentially interact with selective ligands and couple to specific intracellular signaling complexes, finally leading to different functional phenotypes. Hence, different ligands selectively bind to and stabilize the same GPCR at specific conformational states that activate different sets of signaling molecules, producing different cellular effects. [23] This ligand-induced selective signaling (LiSS) is also referred to by others as functional selectivity or biased agonism. [23] The LiSS concept provides an explanation as to why a single GPCR can induce different response patterns by multiple ligands and the existence of so-called full and partial agonists. This realization has led to new opportunities in selective drug design and implications for GPCR deorphanization.
Diverse signaling mediators and pathways
By definition, the large heterotrimeric G-protein complex (G abγ α) is traditionally thought of as the canonical mediator responsible for initiating the signal transduction of GPCRs. [3] The conformational change induced by ligand binding recruits and activates G protein by replacing GDP with GTP on the G a subunit, which dissociates from the tightly bound G bγ subunits. G a-GTP and G bγ subunits then individually initiate different signaling pathways involving various second messengers and effector proteins. The G a-GTP subunit is then re-associated with G bγ subunits after hydrolysis of GTP to GDP by its inherent GTPase activity as well as numerous GTPase-activating proteins (GAPs), allowing a new signaling cycle to start [ Figure 1 ]. [2, 3, 49] G protein can be divided into four major classes based on the functional characteristics of G a subunits:
, and G a12/ 13 . G as stimulates the effector enzyme, adenylyl cyclase, to catalyze the production of cAMP from ATP. This initiates a cAMP-dependent pathway leading to the activation of protein kinase A (PKA), which is able to phosphorylate multiple downstream targets. In contrast, G ai subunit inhibits the production of cAMP. G a q/11 subunit activates phospholipase C-b (PLC b ), which cleaves phosphatidylinositol 4,5-biphosphate (PIP 2 ) into inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 and DAG are two second messengers that activate the release of Ca 2+ and protein kinase C, respectively, promoting further signaling cascades. G a12/13 subunit acts through RhoGEF to activate Rho GTPase family members and regulate actin cytoskeleton remodeling to modulate cell migration. In addition, dissociated G bγ subunits are also known to activate effector molecules such as ion channels and PLC b , thus inducing independent signaling pathways. [50] [51] [52] In recent years, alternatives to the canonical GPCR signaling pathways that expand and/or fine-tune GPCR activity have been identified. GPCRs are known to be phosphorylated by GRKs in a stimulus-dependent manner. Receptor phosphorylation induces b-arrestin binding, which downregulates and desensitizes receptor activity. [53, 54] Later, it was shown that b-arrestins are also involved in clathrin-mediated receptor endocytosis and G-protein-independent signaling by interacting with other signaling machineries such as the Src family, mitogen-activated protein kinases (MAPKs), and phosphatidylinositol 3-kinase (PI3K). [27, 55, 56] In addition, it has recently been shown that some GPCRs can also signal in a G-protein-independent and b-arrestin-independent mechanism by interacting with other GPCR-interacting partners such as JAK2 and PDZ domain-containing protein Na + -H + exchange regulatory factor 1 (NHERF1). [28] More interestingly, some GPCR-interacting partners can also modulate G-protein-dependent signaling positively or negatively by acting as scaffolds to couple downstream signaling molecules closer to GPCRs and G proteins to increase the signaling efficiency or by interfering with GPCR-G protein association to reduce/inhibit G-protein-mediated signaling. [28] Apart from the various signaling mediators and pathways, GPCRs are also known to mediate functional "cross-talk" with other cell surface receptors. GPCR activation, hence, can transactivate other non-GPCR receptors. The best example is the cross-talk between GPCRs and the growth factor receptors. [44, 49, 57, 58] GPCR signaling induced the activity of cell surface sheddases (e.g., matrix metalloproteinases), which cleaved membrane-bound growth factors and led to the activation of growth factor receptors. [59] GPCR activation also can lead to the so-called inside-out signaling of integrin by inducing conformational changes in the extracellular domain and enhancing the ligand-binding affinity of integrins through modification of the intracellular region. [60] [61] [62] Functional and expressional regulation of GPCRs GPCR activity might be modulated through other mechanisms that do not directly involve signaling molecules. For example, receptor dimerization/oligomerization has been established as an important means to regulate the functional expression and/or differential signaling activities of certain GPCRs. [63, 64] It was shown that individual dopamine D 1 and D 2 receptors signal through G as and G ai , respectively, but the D 1 /D 2 heterodimer is instead activated through the G aq pathway. [65] Similarly, the m-d opioid heterodimer was demonstrated to display a different pharmacologic profile from those of the m-or d-homodimers. [66] Functional complementation was observed when two mutant luteinizing hormone receptors (one can interact with ligand but cannot signal and the other is defective in ligand binding but able to signal) were co-expressed. [67] Receptor oligomerization can also rescue and promote the surface expression of immature GPCRs to form a functional heterodimer. For example, when expressed alone, the metabotropic GABA B R 1 isoform was retained in the endoplasmic reticulum (ER) as an immature receptor whereas the GABA B R 2 isoform was expressed efficiently on the surface but could neither bind γ-Aminobutyric acid (GABA) nor induce signals. When the two isoforms were co-expressed, both receptors are delivered to the surface as a functional heterodimer capable of GABA binding and signaling. [68] [69] [70] [71] On the contrary, downregulation of functional GPCRs can be achieved when a dominant negative mutant GPCR is co-expressed and dimerized with the wild-type receptor, retaining the heterodimer in the ER. [72, 73] Receptor oligomerization can also occur between GPCRs and non-GPCRs. During the search of a functional receptor for calcitonin-gene-related peptide (CGRP), it was found that the calcitonin-receptor-like receptor (CRLR), a secretin-class/class B GPCR, needs a co-receptor called receptor-activity-modifying protein 1 (RAMP1) to be efficiently expressed to form a functional CGRPR. [74] Furthermore, when CRLR is dimerized with RAMP2/3, the heterodimers function as a receptor for adrenomedullin that is related to CGRP, but with a different pharmacological profile. [63, 74] More recently, many such RAMP-like nonclassical private GPCR chaperone/escort proteins were identified to interact and facilitate the intracellular trafficking and cell-surface expression of specific GPCRs. [23, 28, 63] The realization that chaperone/escort proteins are needed for the functional expression of GPCRs has led to the development of small molecule pharmacological chaperones to rescue poorly expressed disease-causing mutant GPCRs.
In addition to the functional targeting to cell surface, GPCR expression and activity are also highly regulated by receptor internalization/endocytosis and post-endocytic trafficking. Thus, endocytic sorting can determine the cellular fates of GPCRs by targeting the receptors to lysosome for degradation or recycling to the cell surface. Again, many of these processes are regulated by GPCR-interacting proteins and represent potential targets for chemical intervention. [23, 28] 
Conclusions
GPCRs represent the largest group of cell membrane proteins in human proteome. By transmitting diverse ranges of extracellular signals, GPCRs are critical in cell growth, differentiation, migration, and death. In normal physiology, GPCRs are essential for numerous processes including embryonic development, immunological function, brain development, CNS function, and normal germ cell production. The expression and function of GPCRs are regulated at multiple points during the biosynthesis, intracellular trafficking, ligand binding, and the endocytosis pathway of receptors. GPCRs signal through diverse G-protein-dependent and G-protein-independent mechanisms that involve many intracellular messengers and adaptor proteins. Genetic mutations (deletion, insertion, splicing-defect, nonsense and missense mutations) that render GPCRs defective (totally or partially inactive, constitutively active, inefficient trafficking, etc.) have been increasingly linked to human diseases. Therefore, it is not surprising that GPCRs are the major targets of medicinal drugs currently in use or in development. With the critical findings of the two Nobel Laureates and many others, a much clearer picture is emerging as to how GPCRs work their molecular magic. It is expected that many more GPCRs will soon be deorphanized and structurally defined. As well, extensive GPCR-mediated signaling networks will be mapped in detail. Moreover, better and more specific drugs are being developed to modulate the functions of GPCRs and hopefully control/cure diseases. Therefore, it might not be unrealistic to expect another Nobel Prize in Physiology or Medicine for GPCR-related research in the future.
